HBM Holdings (HKG:2142) said China's National Medical Products Administration approved the investigational new drug application for HBM7004, a bispecific antibody candidate for advanced solid tumors.
The approval follows U.S. clearance in May to begin a Phase I trial, allowing the company to advance clinical development in both markets, according to a Tuesday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.